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Background: Advanced pancreatic cancer confers poor prognosis and treatment advancement has been slow.
Recent randomized clinical trials (RCTs) have demonstrated survival benefits for combination therapy compared to
gemcitabine alone. However, the comparative benefits and harms of available combination chemotherapy
treatments are not clear. We therefore conducted a systematic review and Bayesian network meta-analysis to assess
the comparative safety and efficacy of chemotherapy regimens for the treatment of advanced pancreatic cancer.
Methods: MEDLINE, PubMed, EMBASE, Cochrane Central Registry of Clinical trials and abstracts from major scientific
meetings were searched for RCTs published from 2002 to 2013. Key outcomes were overall survival (OS),
progression free survival (PFS), and safety including grade 3–4 febrile neutropenia, neutropenia, vomiting, diarrhea,
fatigue and sensory neuropathy. Bayesian network meta-analyses were conducted to calculate survival and safety
outcomes using gemcitabine (GEM) as the reference comparator. Effect estimates and 95% credible intervals were
calculated for each comparison. Mean ranks and the probability of being best were obtained for each treatment
analyzed in the network meta-analysis.
Results: The search identified 23 studies involving 19 different treatment regimens and 9,989 patients. FOLFIRINOX,
GEM/cisplatin/epirubicin/5FU (PEFG), GEM/NAB-paclitaxel (NAB-P), GEM/erlotinib+/−bevacizumab, GEM/capecitabine,
and GEM/oxaliplatin were associated with statistically significant improvements in OS and PFS relative to gemcitabine
alone and several other treatments. They were amongst the top ranked for survival outcomes amongst other
treatments included. No significant differences were found for other combination chemotherapy treatments. Effect
estimates from indirect comparisons matched closely to estimates derived from pairwise comparisons. Overall,
combination therapies had greater risk for evaluated grade 3–4 toxicities over gemcitabine alone.
Conclusions: In the absence of head-to-head comparisons, we performed a mixed-treatment analysis to achieve
high-quality information on the effectiveness and safety of each treatment. This study suggests that some combination
therapies may offer greater benefits in the treatment of advanced pancreatic cancer than others. To more fully elucidate
the comparative benefits and harms of different combination chemotherapy regimens, rigorously conducted
comparative studies, or network meta-analysis of patient-level data are required.
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Pancreatic adenocarcinoma is the fourth leading cause of
cancer death in North America [1]. In the United States,
there will be 45 220 new cases in 2013, with 38 460 deaths
due to pancreatic cancer [2]. Prognosis is poor with a five-
year overall survival (OS) rate of 5% for all cases. Due to
the insidious nature of the disease, 80-85% of patients will
be diagnosed with advanced disease at presentation, where
the five-year OS rate drops to only 2% [1].
While supportive care measures such as opioids, radio-
therapy and nerve blocks are critical for optimal symptom
management in patients with advanced disease, systemic
chemotherapy has had the greatest impact on survival.
Since the approval of gemcitabine (GEM) as the standard
first-line therapy in 1997, several new systemic regimens
have been investigated to treat this population [3]. How-
ever, only modest improvements in survival outcomes have
been observed [4]. Agents which have been investigated in
combination with GEM included oxaliplatin, capecitabine,
cisplatin or 5-fluorouracil as well as GEM-based biologic
therapies, erlotinib and more recently the combination of
erlotinib and bevacizumab [5-28]. In 2005, a four-drug
regimen, including GEM, cisplatin, epirubicin, 5-fluorouacil
(PEFG) demonstrated improved overall survival (OS) and
progression free survival (PFS) over GEM alone [19]. In
2011, a four drug regimen, which included folinic acid,
5-fluorouacil, irinotecan and oxaliplatin (FOLFIRINOX),
was shown to have significantly superior survival out-
comes compared to GEM alone [29]. This resulted in the
adoption of FOLFIRINOX as the preferred option for
patients with good performance status (ECOG 0-1/KPS >
70). However, there is controversy as to whether the sur-
vival benefits of four drug combination regimens outweigh
the associated toxicities. More recently, a trial comparing
GEM/NAB-P versus GEM alone demonstrated a statisti-
cally significant survival benefit for this new doublet,
introducing another option for the management of ad-
vanced pancreatic cancer [28]. With the introduction of
these therapeutic options, and the lack of randomized
trials that directly compare all available treatments, it was
of interest to indirectly compare the relative efficacy and
safety of these treatments using a network meta-analysis.
The objective was to perform a comprehensive systematic
review of all phase III randomized clinical trials published
over the last decade comparing GEM to combination
therapies for patients with advanced pancreatic cancer and
compare the relative efficacy and safety of these treatments
using a Bayesian network meta-analysis. The network
meta-analysis incorporates both direct and indirect compa-
risons, using GEM as the reference comparator, in order to
compute the hazard ratios (HR) for OS, and safety out-
comes between all treatments on a relative scale. This
analysis also provides information about the rankings of
various treatments in terms of survival outcomes and safety.Methods
Identification of randomized studies
Randomized studies in any language were searched using
Medline, EMBASE, PubMed and the Cochrane Central
Registry of Controlled Trials over the past decade. The
search strategy included the key words “advanced OR
metastatic AND pancreatic AND (‘cancer’/exp OR cancer)
OR ‘adenocarcinoma’/exp OR adenocarcinoma OR pan-
crea* OR malign* AND (‘neoplasm’/exp OR neoplasm)
AND ‘randomized controlled trial’/de AND ‘pancreas can-
cer’/de and was further filtered in an advanced search for
randomized clinical trials from 2002–2013. Limits included
phase III randomized clinical trials. Abstract presentations
of the American Society of Clinical Oncology (ASCO) and
the European Society of Clinical Oncology were searched
in order to identify any phase III trials that had not been
published. The reference lists of existing systematic reviews
and clinicaltrials.gov were cross-referenced against our
search results in order to identify any additional RCTs.
Two authors (GG and SG) independently screened the ab-
stracts and selected eligible trials. Any discrepancies were
discussed with a third reviewer (DJ). Selected studies were
then assessed for bias and overall study quality using the
SIGN 50 assessment scale [30].Eligibility criteria
Randomized clinical trials with at least two arms compar-
ing different chemotherapy regimens in patients with ad-
vanced pancreatic cancer from January 1st 2002-January
31st 2013 were considered. Clinical trials comparing
chemotherapy either in the form of monotherapy or com-
bination therapy were included if they were either directly
or indirectly connected to the reference comparator,
GEM, and if they enrolled at least 50 patients per arm
based on the recommendations from the literature [31].
The trial population included patients who were eligible
for first-line therapy and who were diagnosed with meta-
static disease. Trials including over 50% of patients with
locally advanced non-metastatic disease in their treatment
arms were excluded from this study because treatment ap-
proaches, response to therapy and outcomes for locally
advanced disease may differ from metastatic disease. Trials
involving radiation therapy were also excluded to avoid
clinical heterogeneity. Phase II trials were excluded from
this study as primary outcomes differ for the majority of
these studies, and potential heterogeneity and bias is fur-
ther introduced due to the lack of blinding and smaller
sample sizes of these studies. Finally, trials including hist-
ology other than adenocarcinoma (e.g. neuroendocrine tu-
mours) were excluded. Interventions of interest included
any single-agent or combination chemotherapy where the
comparators were head-to-head. Outcomes of interest were
OS, PFS and safety.
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Trial data was collected from the original publication in-
cluding the authors’ names, the journal, year of publica-
tion, country of origin, number of participating centers,
inclusion and exclusion criteria, stratification, major and
minor endpoints, number of arms, sample size per arm,
regimens used, doses and line of treatment using a piloted
data extraction form. Patient characteristics were docu-
mented including the ratio of males to females, proportion
of stage IV disease and the proportion of good ECOG or
KPS performance status. Survival outcomes were assessed
from published HR and 95% credible intervals. Where
multiple publications existed for a single randomized clin-
ical trial, only results from the most recent adjudicated
publication were used in the analysis. The Scottish Inter-
collegiates Guidelines Network (SIGN) 50 assessment
scale was used in order to determine the overall methodo-
logical quality of the studies [30]. This was based on an-
swers about sources of funding, internal validity and risk
of bias.
Outcome measures
The primary outcome was OS, calculated as the date of
randomization until the date of death. Secondary outcomes
included PFS and safety. PFS was calculated as the date of
randomization until the date of documentation of disease
progression or death. Differences in the time-dependent
survival outcomes were computed as log HRs within the
network meta-analysis. The ORR was calculated from the
proportion of complete and partial responses as defined in
the ERTCC v 3.0 and divided by the total number of pa-
tients per arm. Grade 3 (serious) or 4 (life-threatening) ad-
verse events of interest were specified a priori and included
febrile neutropenia, neutropenia, fatigue, vomiting, diarrhea
and sensory neuropathy as defined in the Common Ter-
minology Criteria in Adverse Events (CTCAE) v 3.0 [32].
ORR and safety were compared using odds ratios.
Statistical analysis
Descriptive statistics were generated for trial and study
population characteristics across all eligible trials using
SAS (9.2; Cary, NC). Median values were obtained for
each characteristic per arm when applicable, and overall
trial proportions were calculated from data provided in
the trial’s study characteristics.
Pairwise comparisons were generated by synthesizing
studies that compared the same interventions into a
random effects model. Random effects models were used
for the pairwise comparison with the exception of the
use of fixed effects models for comparisons in which
only a single study was included for that particular treat-
ment comparison. The pooled hazard ratios and 95%
confidence intervals were then reported for the out-
comes of interest. All statistical analyses of the meta-analysis were conducted using RevMan [5.2, Cochrane
Collaboration, Copenhagen] [33].
A Bayesian network meta-analysis was performed in
order to simultaneously compare all treatments in the net-
work. The network meta-analysis can be thought of as an
extension of the traditional meta-analysis, as it incorporates
both direct and indirect information through a common
comparator in order to obtain estimates of the relative
treatment effects on the multiple treatment comparisons
[34-37]. For instance, by obtaining information from a trial
comparing drug A to B, and B to C, an indirect estimate of
the benefit of A over C can be achieved [36]. A normal like-
lihood model incorporating log hazard ratios of treatment
differences was used for the analyses. Bayesian methods
combine a prior probability distribution with a distribution
of the pooled effect based on the observed data in order to
obtain a posterior probability distribution of the pooled ef-
fect [35,37,38]. The resulting posterior distribution allows
for its interpretation in terms of probabilities where the
probability of a treatment resulting in a smaller or larger in-
crease of survival can be determined. Furthermore, the pos-
terior results are not influenced by the prior distribution
because non-informative prior distributions are being used
prior to seeing the data, and thus, the posterior distribution
is driven completely by the data [35]. The Bayesian frame-
work for network meta-analyses also allows for the prob-
abilistic interpretation of uncertainty and ranking of
interventions [39]. Therefore, it makes it possible to identify
the most effective treatment and to rank treatments in
order of effectiveness and tolerability.
Gemcitabine, an established standard therapy for ad-
vanced pancreatic cancer, was selected as the reference
comparator in the Bayesian network meta-analysis be-
cause it has consistently been used as the comparator in
the majority of randomized clinical trials available for ad-
vanced pancreatic cancer. Following assessment of hetero-
geneity across trials in terms of patient characteristics,
trial methodologies, and treatment protocols, point esti-
mates and 95% credible intervals were generated. Credible
intervals represent the extent of uncertainty around the
point estimate and thus can be interpreted as the probabil-
istic statement about the parameter [35]. Absolute pro-
longation of survival with various regimens for a patient
was calculated based on the median survival of GEM, the
standard therapy and reference comparator for the net-
work meta-analysis. It was calculated as [(GEM median
OS/Hazard Ratio)-GEM median OS].
The probability of a comparator being optimal was esti-
mated for each outcome and the mean rank was calculated,
by counting the proportion of iterations of the Markov
chain in which each drug had the highest hazard ratio.
Vague or flat priors, such as N (0, 1002) were assigned for
basic parameters throughout [40]. Outcomes were com-
pared from the fixed and random effects models and
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was based on the deviance information criterion and com-
paring the residual deviance with the number of uncon-
strained data points. To ensure convergence was reached,
trace plots and the Brooks-Gelman-Rubin statistic were
assessed. Three chains were fit in WinBUGS for each ana-
lysis, with at least 40,000 iterations, and a burn-in of at
least 40,000 iterations [40]. All Bayesian network meta-
analyses were conducted in WinBUGS 1.4 (MRC Biostat-
istics Unit, Cambridge, UK).
Clinical heterogeneity was first assessed through clinical
judgment with input from experts in the field. Statistical
heterogeneity was then assessed by visually inspecting for-
est plots from pairwise analysis to determine whether there
was overlap in the confidence intervals, as this would sug-
gest heterogeneity. A formal assessment of heterogeneity
was then accomplished by referring to the I2 statistic.
Following standard guidelines, I2 values greater than 50%
are considered high heterogeneity levels, between 25-50%,
moderate and less than 25%, considered low heterogeneity
levels. In instances where heterogeneity was suspected, sen-
sitivity analysis was employed.
Sensitivity analyses were conducted to adjust for im-
portant covariates based the suspicion of heterogeneity
from either the clinical or statistical assessments of het-
erogeneity, as described in the previous sections.
Covariates that were selected to be analyzed in the
Bayesian network meta-analysis, a priori, included patient
performance status, years of publication, trial sample size
and the proportion of stage IV disease versus locally ad-
vanced. The sensitivity analysis for patient performance
status excluded trials conducted with a proportion of pa-
tients with greater than 85% ECOG PS 0-1/KPS of 90–
100, based on clinical recommendations. The sensitivity
analysis for trial size utilized a threshold value of 100 pa-
tients/arm, based on recommendations from Juni et al.
[37]. The sensitivity analysis for stage mix (locally ad-
vanced versus metastatic) excluded trials with 80% or
fewer of patients with stage 4 disease. The analysis for year
of publication excluded any trials conducted prior to 2007.
Results
Description of eligible trials
The initial search of the population resulted in a total of
1747 studies. After removal of duplicates and title/abstract
screening, 83 trials were eligible for full-text screening
resulting in 23 trials that were included in the study
(Figure 1). A search of major scientific meetings yielded
two additional abstracts that were included in the system-
atic review and network meta-analysis.
Characteristics of the included trials are outlined in
Table 1. A total of 9989 randomized patients were in-
cluded in the analysis. The majority of the trials had two
arms and compared GEM to an experimental treatment.Individual trial arms were evenly distributed between age,
gender and performance status. Using the SIGN 50 scale,
5/23 studies (21.7%) were reported as high quality and the
remaining 18 studies (78.3%) as acceptable quality studies.
For the primary outcomes of interest, 19 unique compari-
sons were available for 23 different trials. The resulting
network geometry is depicted in Figure 2.
Results from pairwise comparisons
Pairwise comparisons were accomplished for the 19 differ-
ent comparisons. The weighted hazard ratios for the pri-
mary outcome, OS, were calculated for each comparison.
Statistical heterogeneity was assessed using the I2 statistic,
which was assessable in two of the comparisons, as the
majority of treatments had only been tested in phase III
trials once. The I1 values were 0% for the comparison of
GEM/capecitabine versus GEM alone and GEM/cis-
platin versus GEM alone. In pairwise comparisons, the
combination of GEM/capecitabine, GEM/oxaliplatin,
PEFG, GEM plus NAB-paclitaxel (NAB-P), GEM/erloti-
nib+/−bevacizumab and FOLFIRINOX were associated
with statistically significant hazard ratios for OS over
GEM alone (Additional file 1: Figure S1).
Results from the network meta-analysis of the primary
outcome
The effect estimates from both the fixed and random-
effects models were comparable and matched closely to
the estimates derived from the pairwise comparisons in
both direction and magnitude.
Figure 3 illustrates the hazard ratios for OS and 95%
credible intervals obtained from the indirect comparisons
of the included regimens. Following Figure 3 from left to
right, FOLFIRINOX; PEFG; GEM/NAB-P; GEM/erloti-
nib/bevacizumab; GEM/erlotinib; GEM/capecitabine and
GEM/oxaliplatin were found to have significantly im-
proved survival estimates in comparison to GEM alone.
FOLFIRINOX was associated with statistically significant
hazard ratios for OS relative to fifteen different treatments
including GEM alone and the combinations of GEM with
oxaliplatin; capecitabine; cisplatin; 5-fluorouacil+/−folinic
acid; pemetrexed; irinotecan; exatecan; axinitib; tipifarnib;
marimastat and sorafenib (Additional file 2: Figure S2,
Additional file 3: Figure S3). FOLFINOX had a calculated
OS gain of 4.2 months (95% Cl 2.2-6.9) over GEM alone
and a median survival advantage of 4 months (range 0.8-
6.9 months) over the other treatments included in the ana-
lysis (Table 2). FOLFIRINOX had a 64.9% probability of
being best for OS (Additional file 2: Figure S2 and
Additional file 4: Figure S4). Using the mean rank scale,
FOLFIRINOX was ranked first with a mean rank of 1.5 out
of 20 treatments (Additional file 3: Figure S3). FOLFIRI-
NOX was not associated with statistically significant hazard
ratios for OS compared to GEM/NAB-P [HR 0.79 (0.59-
Figure 1 Flow chart of randomized controlled clinical trials evaluating treatments for advanced pancreatic cancer through
selection process.
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GEM/erlotinib/bevicizumab [HR 0.78, (0.55-1.11)].
GEM/NAB-P was amongst the top-ranked for OS (Mean
Rank 3.8/20) (Additional file 3: Figure S3). It was associ-
ated with a statistically significant benefit in survival over
GEM alone (HR 0.72, 95% CI 0.62-0.82); GEM/cisplatin
(HR 0.73, 95% CI 0.59-0.91); GEM/5FU/FA (HR 0.69,
95% CI 0.54-0.88); GEM/pemetrexed (HR 0.73, 95% Cl
0.58-0.93); GEM/exatecan (HR 0.73, 95% CI 0.57-0.94);
GEM/cetuximab (HR 0.68, 95% CI 0.55-0.84) and GEM/
sorafenib (HR 0.56, 95% CI 0.36-0.88) (Figure 3). GEM/
NAB-P had a median increase of OS time of 2.2 months
(95% CI 1.1-3.4) over GEM alone.
PEFG had improved OS (HR 0.65, 95% CI 0.43-0.98) with
median survival gain of 3 months (95% CI 0.1-7 months)
over GEM alone. It was associated with statistically superior
HR over GEM/cetuximab, GEM/irinotecan, GEM/5FU/FA,
and GEM/sorafenib (Figure 3).
The combination of GEM/erlotinib/bevacizumab was
associatedm with improved survival over GEM alone, as
well as GEM/irinotecan, GEM/sorafenib, GEM/5FU/FA
and GEM/cetuximab (Figure 3). It was ranked fourthfor OS, with a mean rank of 4.3 (Additional file 3:
Figure S3).
GEM/erlotinib (without bevacizumab) was associated
with improved survival over GEM alone (survival gain
1.2 months, 95% CI 0.11-2.57) and over GEM/cetuximab
(Figure 3).
GEM/capecitabine had statistically longer survival than
GEM alone, GEM/sorafenib, GEM/5FU/FA, and GEM/
cetuximab. It was associated with statistically worse OS
compared to FOLFIRINOX (HR 1.43, 95% CI 1.09-1.89).
No other significant differences were observed for the
remaining combination chemotherapy treatments pre-
sented in Figure 3.
Results from the network meta-analysis of the secondary
outcome
The results from the indirect comparisons of FOLFIRINOX
to GEM and the other included treatments, for the second-
ary outcome, PFS, are displayed in Table 2. FOLFIRINOX
was associated with statistically significant hazard ratio for
PFS over thirteen treatments, with the exception of GEM/
NAB-P, GEM/erlotinib/bevacizumab, GEM/pemetrexed,
Table 1 Characteristics of eligible randomized clinical trials included network meta-analysis
Study: Author (year) Study design: number
of patients




Bramhall (2002) RCT-double blinded Gemcitabine
(1000 mg/m2)
Gemcitabine +Marismastat OS Full-text ++
N1 = 119 PFS
N2 = 120 ORR
Berlin (2002) RCT-single blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + 5FU OS Full-text +
N1 = 162 PFS
N2 = 160 ORR
VanCustem (2004) RCT- double blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + Tipifarnib OS Full-text ++
N1 = 344 PFS
N2 = 344 ORR
Rocha Lima (2004) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + Irinotecan OS Full-text +
N1 = 180 ORR
N2 = 180
Louvet (2005) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + Exatecan OS Full-text +
N1 = 156 PFS
N2 = 157 ORR
Reni (2005) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + Oxaliplatin OS Full-text +
N1 = 47 PFS
N2 = 52 ORR
Riess (2005) RCT- single blinded Gemcitabin
(1000 mg/m2)
Gemcitabine + epirubicin +
cisplatin + 5FU
OS Abstract +
N1 = 238 PFS
N2 = 235 ORR
Herrmann (2007) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + 5FU + folinic acid OS Full-text +
N1 = 159 PFS
N2 = 160 ORR
Oettle (2005) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gem + Capecitabine OS Full-text +
N1 = 282 PFS
N2 = 283 ORR
Abou-Alfa (2006) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gem + Pemetrexed OS Full-text +
N1 = 175 ORR
N2 = 1175
Heinemann (2006) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + Cisplatin OS Full-text +
N1 = 97 PFS
N2 = 98 ORR
Stathopoulos (2006) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + Irinotecan OS Full-text +
N1 = 70 ORR
N2 = 60
Poplin (2006) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + Oxaliplatin OS Full-text +
N1 = 275 PFS
N2 = 272 ORR
Moore (2007) 20 RCT- double blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + Erlotinib OS Full-text ++
PFSN1 = 285
N2 = 284 ORR
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Cunningham (2009) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gem + Capecitabine OS Full-text +
N1 = 266 PFS
N2 = 267 ORR
VanCustem (2009) RCT- Double blinded Gemcitabine +
Erlotinib
Gem + Erlotinib + Bevacizumab OS Full-text ++
N1 = 301 PFS
N2 = 306 ORR
Philip (2010) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gemcitabine + Cetuximab OS Full-text ++
N1 = 371 PFS
N2 = 372 ORR
Colucci (2010) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gem + Cisplatin OS Full-text +
N1 = 199 PFS
N2 = 201 ORR
Kindler (2011) RCT-Double blinded Gemcitabine
(1000 mg/m2)
Gem + Axinitib OS Full-text ++
N1 = 315 PFS
N2 = 180 ORR
Conroy (2011) RCT- single blinded Gemcitabine
(1000 mg/m2)
FOLFIRINOX OS Full-text +
N1 = 171 PFS
N2 = 171 ORR
Goncalves (2012) RCT- double blinded Gemcitabine
(1000 mg/m2)
Gem + Sorafenib OS Full-text ++
N1 = 52 PFS
N2 = 52 ORR
Heinemann (2012) RCT-single blinded Gemcitabine +
Erlotinib
Capecitabine + Erlotinib OS Full-text +
N1 = 143 PFS
N2 = 131 ORR
Von Hoff (2013) RCT- single blinded Gemcitabine
(1000 mg/m2)
Gem + NAB-P OS Abstract +
N1 = 430 PFS
N2 = 431 ORR
Gresham et al. BMC Cancer 2014, 14:471 Page 7 of 13
http://www.biomedcentral.com/1471-2407/14/471GEM/irinotecan and PEFG (Table 2). FOLFIRINOX had a
63.1% probability of being best and had a mean rank of
1.38 for PFS (Additional file 4: Figure S4). GEM/NAB-P
was associated with statistically significant hazard ratio for
PFS in comparison to GEM alone and GEM/cisplatin.
Sensitivity analysis of the primary outcome using network
meta-analysis
In order to address possible heterogeneity between trial
populations with regards to covariates such as trial sample
size, year of publication, stage mix, and performance status,
subgroup analyses were performed for the primary out-
come, OS. Overall, results closely resembled the results pre-
sented in the primary network meta-analysis with similar
effect estimates and rankings. Additional file 5: Table S1 in-
dicates the included and excluded trials for each of the sen-
sitivity analyses. Specifically, for the subgroup of trials
including at least 100 patients per arm (n = 19 trials), FOL-
FIRINOX, GEM/NAB-P and GEM/erlotinib/bevacizumab
were the top-ranked treatments where FOLFIRINOX wasassociated with statistically significant hazard ratio for
OS over all treatments except for GEM/NAB-P (HR: 0.85,
95% Cl 0.47-1.33) and GEM/erlotinib/bevacizumab (HR:
0.90, 95% Cl 0.41-1.48). Similar findings were observed for
the subgroup of RCTs published after 2007. In the sensitiv-
ity analysis excluding trials with a significant proportion of
non-metastastic, locally advanced disease (proportion with
metastases < 80%), 15 trials were included. FOLFIRINOX
was associated with statistically significant hazard ratio for
9 out of 15 possible combinations, not including GEM/
NAB-P, GEM/erlotinib/bevacizumab, gem/erlotinib, gem/
oxaliplatin and gem/capecitabine.
Finally, the sensitivity analysis for poor performance sta-
tus excluded seven trials where the proportion of patients
with ECOG ≥ 0-1 (or KPS <90) was less than 15%. GEM/
NAB-P was ranked first for OS and was associated with
statistically significant hazard ratio for survival over GEM
alone (HR 0.72, 95% CI (0.54-0.95)). GEM/erlotinib/bev
and GEM/bev were also associated with significant OS
over GEM alone. Both FOLFIRINOX and PEFG were
Figure 2 Network of eligible trials where center node represents the reference comparator: Gemcitabine. Circle size is proportionate to the
number of patients, thickness of line represents number of trials per comparison and distance of circle to reference comparator (gemcitabine) is
proportionate to year of publication where 1 cm = 2 years. Gem = gemcitabine. 5FU = 5-fluorouacil. FA = Folinic Acid. Erlo = erlotinib. Epi = epirubicin.
Bev = bevacizumab. Cape = capecitabine. Soraf = sorafinib. M =marismastat. Cis = cisplatin. Irino = irinotecan. Oxali = oxaliplatin. Tipif = tipifarnib.
Cetux = cetuximab. NAB-P = NAB-Paclitaxel.
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tions were observed in the remaining comparisons.
Assessment of safety using indirect comparisons
of regimens
An a priori decision was made to assess grade 3–4 neutro-
penia, febrile neutropenia, fatigue, diarrhea, sensory neur-
opathy and vomiting, in a Bayesian network meta-analysis.Figure 3 Indirect comparisons for overall survival: HRs and 95% CIs fo
Control; Vertical: Control vs. Experimental. HR < 1 indicates OS or PFS benefit
5-flurouacil; PEFG = gemcitabine + epirubicin + 5FU + cisplatin; NAB-P = NAB-P;
oxaliplatin; tipif = tipifarnib; pem = pemetrexed; cis = cisplatin; irino = irinotecanOdds ratios and 95% credible limits were obtained for each
grade 3–4 toxicity comparison where treatments were
ranked in order of highest toxicity rates to lowest based on
the odds ratios found in the comparisons. Overall, GEM
was found to be associated with the smallest risk for grade
3–4 toxicities evaluated in this study.
Additional file 6: Figure S5 summarizes the odds ra-
tios of adverse outcomes in patients treated with eitherr various treatment comparisons. Horizontal: Experimental vs.
. *Hazard ratios are statistically significant. Gem = gemcitabine; 5FU =
bev = bevacizumab; erlo = erlotinib; cape = capecitabine; oxali =
; FA = folinic acid; cetux = cetuximab; soraf = sorafenib.
Table 2 Indirect comparisons of available treatments for advanced pancreatic cancer
Indirect comparison Overall survival Survival gain over OS** Progression free survival** Progression free survival gain
HR (95% CI) Months (95% CI) HR (95% CI) Months (95% CI)
FOLFIRINOX vs.
Gemcitabine 0.57 (0.45-0.72)* 4.22 (2.12-6.92)* 0.59 (0.37-0.47)* 3.73 (0.98-6.48)*
Gemcitabine + NAB-P 0.79 (0.59-1.05) 1.46 (−0.27-3.81) 0.68 (0.51-0.91)* 1.54 (0.32-3.16)*
Gemcitabine + Oxaliplatin 0.66 (0.50-0.88)* 2.83 (0.76-5.59)* 0.60 (0.43-0.85)* 2.17 (0.58-4.43)*
Gemcitabine + Capecitabine 0.70 (0.53-0.92)* 2.42 (0.48-5.0) 0.58 (0.45-0.74)* 2.40 (1.14-4.01)*
Gemcitabine + Cisplatin 0.58 (0.43-0.78)* 4.06 (1.62-7.3) 0.46 (0.34-0.62)* 3.94 (2.03-6.53)*
Gemcitabine +5FU 0.70 (0.49-0.97)* 2.45 (0.17-5.63)* 0.61 (0.44-0.84)* 2.11 (0.63-4.14)*
Gemcitabine + 5FU/FA 0.55 (0.40-0.74)* 4.62 (1.93-8.28)* n/a n/a
Gemcitabine + pemetrexed 0.58 (0.43-0.74)* 4.03 (1.51-7.41)* n/a n/a
Gemcitabine + irinotecan 0.55 (0.39-0.76)* 4.62 (1.76-8.54)* n/a n/a
PEFG 0.88 (0.54-1.43) 0.80 (−1.66-4.76) 0.92 (0.57-1.48) 0.28 (−1.07-2.47)
Gemcitabine + exatecan 0.58 (0.43-0.79)* 4.03 (1.44-7.53)* n/a n/a
Gemcitabine + erlotinib 0.70 (0.51-0.94)* 3.94 (1.47-3.94)* 0.61 (0.45-0.82)* 2.11 (0.72-3.96)*
Gemcitabine + erlotinib + bevacizumab 0.78 (0.55-1.11) 1.57 (−0.55-4.61) 0.63 (0.45-0.88)* 1.95 (0.44-4.08)*
Gemcitabine + axinitib 0.56 (0.40-0.80)* 4.36 (1.40-8.54)* 0.47 (0.33-0.66)* 3.76 (1.70-6.68)*
Gemcitabine + tipifarnib 0.59 (0.44-0.79)* 3.94 (1.47-7.27)* 0.64 (0.48-0.86)* 1.82 (0.54-3.54)*
Gemcitabine +marismastat 0.58 (0.40-0.83)* 4.13 (1.18-8.38)* 0.49 (0.35-0.70)* 3.37 (1.41-6.15)*
Gemcitabine + Sorafenib 0.45 (0.28-0.73)* 6.89 (2.11-14.6)* 0.45 (0.28-0.72)* 4.00 (1.30-8.32)*
Gemcitabine + Cetuximab 0.54 (0.40-0.71)* 4.82 (2.24-8.25)* 0.44 (0.33-0.58)* 4.21 (2.41-6.56)*
Capecitabine + erlotinib 0.68 (0.46-1.00) 1.08 (0.67-6.30) 0.60 (0.88-1.30) 0.76 (0.43-2.20)
*Statistically significant, n/a = comparison not available.
Hazard ratios for overall survival and progression free survival for FOLFIRINOX with relation to all included treatments in the network-meta-analysis are shown.
**Survival gain/PFS gain calculated from [(Gemcitabine median OS/HR)-Gemcitabine median OS]/[(Gemcitabine median PFS/HR)-Gemcitabine median PFS].
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http://www.biomedcentral.com/1471-2407/14/471GEM/NAB-P or FOLFIRINOX, the top-ranked regi-
mens in this analysis. Some important findings include
the significantly increased odds for grade 3–4 neutro-
penia observed in patients treated with FOLFIRINOX
compared to those treated with GEM/NAB-P (OR 1.92,
95% CL 1.10-3.39), GEM/cisplatin, GEM/capecitabine,
GEM/tipifarnib and GEM/erlotinib/bevacizumab. PEFG
was associated with statistically significant increased odds
for neutropenia relative to the majority of the other com-
bination treatments.
FOLFIRINOX, GEM/NAB-P, GEM/Pemetrexed and
GEM/Irinotecan were associated with significantly
greater odds for grade 3–4 febrile neutropenia com-
pared to GEM alone. GEM/pemetrexed was associated
with the greatest risk for grade 3–4 febrile neutropenia
with statistically significant odds ratios over GEM alone,
GEM/NAB-P, GEM/cisplatin, and GEM/oxaliplatin. It
was not statistically different than FOLFIRINOX. No
other treatments were found to be associated with statisti-
cally significant odds ratios relative to each other in this
analysis.
For grade 3–4 diarrhea, GEM/oxaliplatin, GEM/cis-
platin, GEM/pemetrexed, FOLFIRINOX, Gem/NAB-Pand GEM/erlotinib were associated with significantly
greater odds for diarrhea compared to GEM alone. In
this analysis, GEM/erlotinib/bevacizumab had the lowest
risk for grade 3–4 diarrhea.
GEM/NAB-P had greater odds of grade 3–4 fatigue over
seven other treatments: GEM/tipifarnib, GEM/exatecan;
GEM/oxaliplatin; GEM/erlotinib; GEM/capecitabine; GEM/
cetuximab; GEM/erlotinib/bevacizumab. It was not statisti-
cally different than GEM/pemetrexed, PEFG, GEM/cisplatin
or FOLFIRINOX, although it trended towards increased risk
for grade 3-4 fatigue in comparison to FOLFIRINOX
(OR: 1.90, 95% CL 0.94-3.88) (Additional file 6: Figure S5).
GEM/cisplatin, GEM/oxaliplatin, GEM/cetuximab and
cisplatin/exatecan were associated with greater odds of
grade 3–4 vomiting over GEM alone. GEM/cisplatin and
GEM/oxaliplatin also had greater odds of vomiting relative
to PEFG, GEM/marismastat, GEM/5FU and GEM/tipifar-
nib. GEM/exatecan and FOLFIRINOX had greater odds
of vomiting over GEM/tipifarnib. Grade 3–4 vomiting in
patients treated with GEM/NAB-P was not evaluable as
data was not available.
FOLFIRINOX was ranked worse for grade 3–4 sensory
neuropathy out of six treatments with available data (GEM/
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NAB-P). All included treatments in the analysis had statisti-
cally significant increased risk for grade 3–4 sensory neur-
opathy compared to GEM alone. However, none of them
were found to be associated with statistically significant
odds ratios over other included combination therapies.
Overall, there were no statistically significant differences
in odds ratios for febrile neutropenia, fatigue, diarrhea or
sensory neuropathy between FOLFIRINOX versus GEM/
NAB-P with the exception of grade 3–4 neutropenia
(Additional file 6: Figure S5).
Discussion
In the absence of head-to-head comparisons, we performed
a network meta-analysis that evaluates the efficacy and
tolerability of current treatments available for advanced
pancreatic cancer, including four new combination regi-
mens that have emerged since previously published meta-
analyses [11,24,28,29]. Our study found that in comparison
to GEM alone, there was statistically significant improved
survival associated with FOLFIRINOX, PEFG, GEM/NAB-
P, GEM/capecitabine, GEM/erlotinib with or without beva-
cizumab and GEM/oxaliplatin. Furthermore, in comparison
to other GEM-based doublets included in this analysis, our
ranking found that FOLFIRINOX, PEFG, GEM/NAB-P,
GEM/erlotinib with or without bevacizumab, GEM/capecit-
abine and GEM/oxaliplatin were also associated with better
survival. We found that, although combination therapies
generally improve survival outcomes in patients with meta-
static pancreatic cancer, they were also associated with
greater odds for grade 3/4 adverse events over GEM alone.
In particular, FOLFIRINOX and PEFG were both associated
with significantly greater odds for adverse events including
grade 3/4 neutropenia and grade 3/4 diarrhea. Gem/NAB-P,
was found to be associated with the highest risk for grade
3/4 fatigue relative to other combination therapies included
in the analysis.
Initial efforts to combine GEM with other therapies in
the form of doublets have lead to a stream of statistically
negative trials that were redeemed only through meta-
analysis suggesting some benefit for combination with plat-
inums or capecitabine. In contrast, recent large multi-
center trials offer promising results with regimens including
FOLFIRINOX [29] and GEM/NAB-P [28]. In selecting
some of these regimens (FOLFIRINOX, PEFG), investiga-
tors have abandoned the traditional stepwise approach of
adding a single new agent to assess the specific contribution
of that agent to outcome. This approach, while obscure
from a regulatory and purely scientific perspective, has met
with clinically meaningful success. However, survival bene-
fits with these more aggressive yet still palliative treatment
must be weighed against the associated increased toxicities.
Although other systematic reviews and meta-analyses
have been conducted to evaluate chemotherapy regimensin advanced pancreatic cancer, they have only reflected re-
sults of direct comparisons and information about safety
and treatment rankings are limited and pre-date the recent
phase III trials in this setting that evaluated treatments such
as FOLFIRINOX, GEM/NAB-P, GEM/erlotinib/bevacizu-
mab and erlotinib/capecitabine [3,41-50]. Therefore, it is
often difficult to determine the most effective treatment.
Unique to this analysis, Bayesian statistics were used to ac-
complish a mixed-treatment analysis where high-quality in-
formation on the effectiveness and safety of each treatment
was achieved.
Results from previously published systematic reviews
are similar to our own findings where meta-analyses have
reported the combination of GEM with capecitabine as
being significantly associated with a survival benefit com-
pared to GEM alone [3,45] as well as the combination of
GEM/erlotinib [50], which we also found in both our direct
and indirect comparisons. A comparison of our own find-
ings to those of published systematic reviews assessing the
survival benefits of more recent combination treatments,
including FOLFIRINOX and GEM/NAB-P is not yet pos-
sible as most published reviews pre-date the more recent
phase III trials. However, a Cochrane review protocol was
published in June 2013 that will compare both single agent
and combination chemotherapy in pancreatic cancer [48].
A previously published meta-analyses reported that pa-
tients with ECOG performance status 0–1 had greater
benefit from combination treatment while patients with
worse performance did not [41]. This result may help ex-
plain why the exclusion of trials with more than 85%
of patients with an ECOG performance status 0–1 re-
sulted in more conservative treatment effects where
GEM/NAB-P and GEM/erlotinib +/−bev, were associated
with improved OS compared to GEM alone but no other
combination treatments. Confounding may explain these
findings, as patients with ECOG performance status 0–1 are
often healthier, younger and more likely to tolerate more ag-
gressive regimens such as PEFG or FOLFIRINOX. There-
fore, the results in the RCTs that included a large proportion
of patients with high performance status may not be repre-
sentative, and further research assessing the performance
of such combination treatments in a more heterogeneous
population in terms of performance status is needed.
The intent of this network meta-analysis is to provide
an overall impression of the benefits and risks of these
chemotherapeutic options for the first-line treatment of
metastatic pancreatic cancer on a relative scale, using haz-
ard ratios as the preferred time-to-event measures. Results
from this network meta-analysis may guide physicians in
the recommendations of different treatments in the ab-
sence of head to head comparisons. There are, however,
limitations to this approach that warrant cautious inter-
pretation of the results. Factors such as trial heterogeneity,
bias and inconsistency can affect the estimates reported in
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on the assumption of consistency where the validity of in-
direct comparisons was determined by the extent of clin-
ical and methodological trial similarity. However,
inconsistency remains a methodological issue of multiple
treatment comparisons, as it arises from pooling the data
and small number of trials available for the different com-
parisons resulting in discrepancies between the direct and
indirect comparisons, and consequently threatening the
validity of the results [51-53]. In the case of our network
meta-analysis, the indirect estimates were often very simi-
lar to those obtained in the direct comparisons because
only single comparisons were available for the majority of
the cases. This resulted in a less conventional geometry,
where our network of trials did not have closed pathways
(Figure 2).
Also, differences in study populations, interventions, trial
design, and outcomes definitions introduce potential con-
founding and bias to the analysis, where baseline differ-
ences in trial populations may have affected the outcomes.
For example, FOLFIRINOX included better prognosis pa-
tients (99% ECOG performance status of 0–1) and had a
larger majority of males in the study, which may have al-
tered effect estimates. In attempt to adjust for possible dif-
ferences in trial populations, sensitivity analyses were
performed. Results and effect estimates were comparable to
results from the network meta-analysis. However, when
treatments were analyzed in a sensitivity analysis for per-
formance status, FOLFIRINOX and PEFG were excluded
from the analysis, and consequently, GEM/NAB-P was
identified as the optimal treatment in our rankings.
Another limitation of our analysis was that not all ad-
verse event outcomes of interest were reported consist-
ently across trials, particularly for febrile neutropenia
and sensory neuropathy. Furthermore, there were cases
where no events had occurred for the outcome of interest
resulting in the requirement to add a continuity correction
to the results [53]. Furthermore, not all outcomes were
assessed using network meta-analysis due to missing data
or different reporting methods, such as the case of quality-
of-life where it could not be adequately assessed using net-
work meta-analysis. In general, missing data resulted in
wider credible intervals due to greater uncertainty around
the estimates. Furthermore, dose adjustment of FOLFIRI-
NOX is frequently required due to adverse events, such
that a variety of modified FOLFIRINOX regimens are
widely used in clinical practice. However, no trials exist to
compare these various modified FOLFIRINOX schedules
to GEM alone, creating some uncertainty about the efficacy
and toxicity of the modified schedules. In light of the limita-
tions discussed above, these results should be interpreted
alongside differences in absolute effects such as survival
gain in months and hazard ratios should be used as guides
for physicians and not as definitive values.Conclusions
In conclusion, this study suggests that the use of combin-
ation therapy in the treatment of advanced pancreatic can-
cer may offer a greater survival benefit over GEM alone. It
also allowed for the indirect comparison between combin-
ation therapies, including recent regimens, where head-to-
head comparisons have not been available. GEM doublets
such as GEM/capecitabine and GEM/oxaliplatin, GEM/er-
lotinib as well as GEM-based three or four drug regimens
such as GEM/erlotinib/bevacizumab and PEFG and finally
more recent treatments such as FOLFIRINOX and GEM/
NAB-P all have achieved statistically significant survival
benefits over GEM alone as well as several other combin-
ation therapies.
Whether these treatments should be tested in a large
multi-center randomized clinical trial, or whether the choice
of treatment is left to the physician’s discretion, is the subject
of debate. To fully elucidate the comparative effectiveness,
rigorously conducted comparative studies among more
similar populations, or network meta-regression analyses
of patient-level data are required. Further, given the differ-
ences in costs of treatments, a cost-effectiveness analysis is
warranted. Nonetheless, the application of network meta-
analysis in this setting can help inform current therapeutic
decision-making and direct the design of future studies.
Additional files
Additional file 1: Figure S1. Forest plot of pairwise comparisons for
overall survival of individual trials.
Additional file 2: Figure S2. Forest plot of hazard ratios for overall and
survival (left) and progression free survival (right) for all comparisons of
FOLFIRINOX with other treatments included in network meta-analysis.
Additional file 3: Figure S3. Mean rank for overall survival for
treatments included in Bayesian network meta-analysis. A low mean rank
indicates the greatest overall survival relative to other treatments. Gem =
gemcitabine; 5FU = 5-flurouacil; PEFG = gemcitabine + epirubicin + 5FU +
cisplatin; NAB-P = NAB-Paclitaxel; bev = bevacizumab; erlo = erlotinib;
cape = capecitabine; oxali = oxaliplatin; tipif = tipifarnib; pem = pemetrexed;
cis = cisplatin; irino = irinotecan; FA = folinic acid; cetux = cetuximab; soraf =
sorafenib.
Additional file 4: Figure S4. Probability of a treatment being best out
of 100% for overall survival and progression free survival.
Additional file 5: Table S1. Summary of included/excluded studies in a
priori sensitivity analyses.
Additional file 6: Figure S5. Forest plot of adverse outcomes in
patients treated with either gemcitabine + NAB-P or FOLFIRINOX where
an odds ratio >1 indicates higher risk of toxicities for patients treated
with FOLFIRINOX.
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